Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene study reveals hidden breast cancer risks in young women

NCT ID NCT04206891

Knowledge-focused Sponsor: European Institute of Oncology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 421 women with lobular breast cancer to see how often they have changes in the CDH1 gene. The goal was to understand if these gene changes raise the risk for breast cancer, especially in women diagnosed at a young age or in both breasts. Researchers collected blood samples and analyzed the gene to find patterns that could help identify high-risk women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

421 people

The number who actually took part.

Started

Dec 2018

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

From 1997 to 2016 we collected data from a total of 1544 patients with invasive LBC and 230 with in situ histotype. For CDH1 genetic screening, an additional population will be considered prospectively between the range 2017-2018 Among them we will have to identified patients with a BRCA1/2 pathogenetic mutation.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Bilateral lobular breast cancer or Lobular breast cancer with age at onset \<= 45 years or Lobular breast cancer with family history for breast cancer * Patients with blood available in IEO biobank Exclusion Criteria: * Patients with a previous cancer (except for colon cancer, stomach cancer and lobular breast cancer). * Patients with germline BRCA1/2 patogenetic mutation will be excluded

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CDH1 gene inactivation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast lobular carcinoma Carcinoma, Lobular

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CDH1 gene inactivation Lobular breast carcinoma

Contacts and locations

Locations

  • European Institute of Oncology

    Milan, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.